LESSONS LEARNED FROM THE AMP TRIAL: IS THE GLASS HALF FULL?
The AMP (Antibody Mediated Prevention) trial was the first study to show that a broadly neutralizing antibody (bnAb), VRC01, could prevent HIV-1 acquisition. However, this protection was incomplete, with VRC01 only blocking highly sensitive viruses. Here we will explore innate and selected resistance in breakthrough infections from this trial. Using an updated virus panel, we…